Unnatural Products Announces BridgeBio Exercises Option To License Macrocyclic Peptide Candidates Discovered Using UNP's AI-Enabled Massively Parallel Chemistry Platform
Unnatural Products Announces BridgeBio Exercises Option To License Macrocyclic Peptide Candidates Discovered Using UNP's AI-Enabled Massively Parallel Chemistry Platform
Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today that BridgeBio Pharma, Inc. (NASDAQ:BBIO), has exercised its option to license macrocyclic peptide candidates discovered using UNP's AI-enabled massively parallel chemistry platform.
Unnatural Products, Inc.（UNP）是一家开发口服大环肽以解决以前无法药物治疗的靶标的生物技术公司（UNP）今天宣布，BridgeBio Pharma, Inc.（纳斯达克股票代码：BBIO）已行使选择权，对使用UNP的人工智能大规模平行化学平台发现的大环肽候选物进行许可。
This milestone signifies a significant milestone in the collaboration between the two companies, and reinforces the potential of macrocyclic peptides as a novel therapeutic modality for rare diseases and oncology. Macrocyclic peptides are a unique class of therapeutic compounds characterized by large, cyclic structures that offer significant advantages over traditional therapies such as small molecules and monoclonal antibodies. Their unique structure provides high stability, potent binding affinity, and the ability to access difficult-to-reach intracellular targets, positioning them as a promising therapeutic class.
这一里程碑标志着两家公司合作中的一个重要里程碑，也增强了大环肽作为罕见疾病和肿瘤学新疗法的潜力。大环肽是一类独特的治疗化合物，其特征是大型循环结构，与小分子和单克隆抗体等传统疗法相比，具有显著的优势。它们独特的结构具有高稳定性、强大的结合亲和力，并能够获得难以到达的细胞内靶标，使其成为前景广阔的治疗类别。
